Protosappanin A NEW
| Price | $89 | $228 | $372 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Protosappanin A | CAS No.: 102036-28-2 |
| Purity: 99.42% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Protosappanin A |
| Description | Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/I?oB/NF-?oB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM. |
| In vitro | Protosappanin A (PsA) and Protosappanin B (PsB) were identified from Sappan Lignum extracts. They showed activity against both S. aureus and MRSA with MIC or MIC50 at 64 (PsA) and 128 (PsB) mg/L alone. When they were used in combination with antibiotics, they showed the best synergy with amikacin and gentamicin with MIC50 (mg/L) of amikacin reduced more significantly from 32 to four (with PsA) and eight (with PsB), and the fractional inhibitory concentration index (FICI) ranged between 0.078 and 0.500 (FICI50 = 0.375). Moreover, the resistance of MRSA towards amikacin and gentamicin could be reversed by the Clinical and Laboratory Standards Institute criteria. The combined bactericidal mode could as well be synergy. PsA and PsB showed very low cytotoxicity in comparison with their promising activity against MRSA[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 225 mg/mL (826.45 mM) |
| Keywords | STAT | Protosappanin A | Janus kinase | JAK | Inhibitor | inhibit |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Acetylcysteine | Dextran sulfate sodium salt (MW 4500-5500) | Acetaminophen | Hydroxychloroquine | Lamivudine | Valproic Acid | Diallyl disulfide | Salicylic acid | Decanedioic acid |
| Related Compound Libraries | Polyphenolic Natural Product Library | Traditional Chinese Medicine Monomer Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Neuroprotective Compound Library | Natural Product Library for HTS | Anti-Aging Compound Library | Anti-infective Natural Product Library | Immunology/Inflammation Compound Library | Anti-virus Traditional Chinese Medicine Monomer Library | Bioactive Compounds Library Max | Ancient Chinese Classical Formulas Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $890.00/10g |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-08 | |
| $0.00/1g |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-06 | |
| $0.00/1KG |
VIP3Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2022-09-22 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY